

[EBMT](#)

[Annual report](#)

[2022](#)



[ScienceEducationPatient Care & Advocacy](#)

[Our SocietyOur Mission, Vision & ValuesEquality, Diversity & InclusionEBMT](#)

[Membership 2022Organisational Structure 2022Financial Highlights 2022EBMT](#)

[Partners](#)

## Breadcrumb

1. [Home](#)

## Entity Print



Fabio Ciceri

ALWP Chair (ELECTED MARCH 2022, PREVIOUS CHAIR: Mohamad Mohty)

Italy

## Major achievements

The activity of the ALWP continues to increase thanks to the great contribution of the ALWP members and collaborators and the continuous efforts of the ALWP staff. We receive constant demonstration of appreciation by a continuous increase in the study proposals, and for this I really recognize the unique dedication and

commitment of the entire ALWP staff, and I am grateful for that. The established organisation of ALWP in sub-committees reflects the wide area of interests and improves both continuity of investigators and participation in a scenario of high rate of scientific production.

The number of transplants for patients with acute leukaemia is constantly growing, with increase in the HCT indications, as well the age of the patients and diseases. New drugs are available for both conditioning regimens and maintenance therapies, as well post-transplant management to decrease disease recurrence and non-relapse mortality. ALWP achieved a great number of peer reviewed publications, as it happens during the previous years, in key high impact factor journals, and presentations to international conferences on haematology and transplants.

In line with the scientific initiative started last year, ALWP is still collecting the data on next-generation sequencing (NGS) data and use of novel drugs, with the aim to improve the quality of the registry and the scientific output of the publication to the benefit of the patient's care.

I am very grateful for tireless efforts in sending such complex data, which will definitely lead to the generation of new knowledge to further advance the management of acute leukaemia.

## **Principal research studies**

[Trends in allogeneic stem cell transplantation \(HSCT\) over two decades in patients with secondary acute myelogenous leukemia \(sAML\) being transplanted from sibling \(MSD\) or unrelated donors \(UD\). A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Myeloid Leukaemia \(AML\)](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[Type of Stem Cell Treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Arnon Nagler](#)

[Long term outcomes and relative mortality in survivors of allogeneic hematopoietic cell transplantation in acute myeloid leukemia: an analysis from the ALWP of the EBMT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Myeloid Leukaemia \(AML\)](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[Type of Stem Cell Treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Vivek Patel](#)

[Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Myeloid Leukaemia \(AML\)](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[Type of Stem Cell Treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Ali Bazarbachi](#)

## **Key publications**

[2022](#)

[Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Arnon Nagler](#)

[Journal](#)

[Am J Hematol.](#)

[2022](#)

[Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Arnon Nagler](#)

[Journal](#)

[Clin Cancer Res.](#)

[2022](#)

[Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Arnon Nagler](#)

[Journal](#)

[Hemasphere.](#)

[2022](#)

[Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Michele Wieczorek](#)


[Journal](#)

[Am J Hematol.](#)

[See the full list of the ALWP 2022 publications](#)



Impact factor  
(Acute Leukaemia)



#### 2019 2020 2021 2022

<b>Oral presentations</b>	24	12	10	<b>15</b>
<b>Poster presentations</b>	17	12	8	<b>22</b>
<b>Educational events</b>	1	2	0	<b>4</b>

## Major educational events



## [Event](#)

### [\*\*Virtual 48th Annual Meeting of the EBMT\*\*](#)

[Mar 19, 2022 - Mar 23, 2022 / Online](#)

[Discover more](#)

- 48th Annual Meeting of the EBMT: ALWP session ALWP - Advances in ALL therapy - March 22, 2022
- 48th Annual Meeting of the EBMT: ALWP Scientific Business Meeting - March 22, 2022
- ALWP Scientific Business Meeting - Sep. 30, 2022
- Joint Meeting of the ALWP and CTIWP (Virtual) - Sep. 30 - Oct. 1, 2022

[VISIT THE ALWP WEBPAGE](#)